表紙
市場調査レポート

ヒストンメチルトランスフェラーゼ:研究ツール・診断・創薬の世界市場

Histone Methyltransferases: Global Markets for Research Tools, Diagnostics and Drug Discovery

発行 BCC Research 商品コード 264964
出版日 ページ情報 英文 164 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
ヒストンメチルトランスフェラーゼ:研究ツール・診断・創薬の世界市場 Histone Methyltransferases: Global Markets for Research Tools, Diagnostics and Drug Discovery
出版日: 2013年03月25日 ページ情報: 英文 164 Pages
概要

当レポートでは、世界のヒストンメチルトランスフェラーゼ(HMT)市場および商業的可能性について調査し、世界市場の実績データとCAGR予測を含む市場動向、エピジェネティックスの歴史、主要エピジェネティック酵素の説明、HMTのターゲット、各細胞機能におけるHMTの重要性、各疾病におけるHMTの役割、HMT用試薬・アッセイプロバイダーと研究ツール開発の評価、HMTアッセイ開発の特許分析、HMT創薬における現在のパイプラインと候補薬、および主要企業のプロファイルなどをまとめ、概略下記の構成でお届けいたします。

第1章 イントロダクション

第2章 サマリー

第3章 ヒストンメチルトランスフェラーゼ研究・製品開発のイントロダクション

  • 概要
  • DNAメチル化
  • ヒストン修飾

第4章 ヒストンメチルトランスフェラーゼ研究・製品開発用の研究ツール・試薬の開発

  • 概要
  • ヒストンメチルトランスフェラーゼ(HMT)研究に必要な試薬・アッセイ

第5章 創薬・治療開発におけるヒストンメチルトランスフェラーゼ

  • 概要
  • HMT創薬市場の参入企業
  • 開発中の現在の候補薬・HMT阻害薬
  • 市場開発・活動の指標としてのエピジェネティックス市場における契約
  • HMT研究関連のさらなる創薬標的

第6章 診断・バイオマーカー開発におけるヒストンメチルトランスフェラーゼ

  • 概要
  • 肺がんとヒストン修飾
  • 前立腺がんとヒストン修飾
  • 乳がんとヒストン修飾
  • 白血病とヒストン修飾
  • 食道・胃がんとヒストン修飾
  • 腎臓・肝臓・膵臓がんにおけるヒストン修飾
  • エピジェネティックス領域における市場参入企業

第7章 ヒストンメチルトランスフェラーゼ研究・製品開発における特許の重要性

第8章 市場サマリー

第9章 主要企業のプロファイル

第10章 企業プロファイル

  • CELLCENTRIC LTD.
  • CONSTELLATION PHARMACEUTICALS
  • DOMAINEX
  • EPITHERAPEUTICS APS
  • EPIZYME, INC.
  • エーザイ
  • GLAXOSMITHKLINE (GSK)

第10章 本書で言及した企業のリスト

図表リスト

目次
Product Code: PHM128A

This report provides:

  • An overview of the global market and commercial potential for histone methyltransferases (HMTs)
  • Analyses of global market trends, with data for 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
  • Discussion of the history of epigenetics, descriptions of main epigenetic enzymes, targets for HMTs, the importance of HMTs in different cellular functions, and the role of HMTs in different diseases
  • Market participants providing reagent and assay for HMT research, and estimates and evaluation in research tool development
  • Patent analysis in HMT assay development
  • Current pipelines and drug candidates in HMT drug discovery
  • Comprehensive company profiles of major players.

SAMPLE FIGURE
GLOBAL MARKET FOR HISTONE METHYLTRANSFERASES RESEARCH AND
DEVELOPMENT, 2011-2018 ($ MILLIONS)

Source: BCC Research

STUDY GOALS AND OBJECTIVES

This BCC Research report, Histone Methyltransferases: Global Markets for Research Tools, Diagnostics and Drug Discovery, provides an overview of the current overall state of the histone methyltransferases market, focusing specifically on tools and reagents, drug discovery trends and diagnostic potential. It describes existing platforms and technologies on the market, and a detailed analysis of the competitive environments, including new trends and segments for novel products and assay development. This study includes information about significant players, trends, and obstacles and other information affecting this market and its different sectors. Overall, this report will forecast current and future trends and developments in the histone methyltransferases segment and its potential market and partnerships for 2013 to 2018.

REASONS FOR DOING THIS STUDY

Epigenetics is defined as the study of heritable changes in gene expression caused by modifications other than changes in the DNA sequence. In eukaryotes, genomic DNA is packaged with histone proteins into the cell nucleus as chromatin. Examples of such modifications are DNA methylation and various histone modifications, both of which regulate gene expression without altering the underlying DNA sequence. Consequently, such modifications are not only important for proper development but can cause many pathological conditions including cancer.

Epigenetics is a very complex scientific discipline. It includes many molecular “players” essential for proper cell function. During the last decade, substantial efforts in epigenetics drug discovery were made. Today, the market for epigenetic therapeutics was evaluated by some analysts at over $600 million, based on sales of four products: Dacogen from Eisai, Vidaza and Istodax from Celgene, and Zolinza from Merck, which target two epigenetic pathways-DNA methyltransferases (DNMT) and histone deacteylases (HDAC).

Histone methyltransferases are another group of important epigenetic enzymes responsible for proper gene expression and silencing. For example, Ezh2 is one of the most well-studied histone methyltransferases. Over the past decade, it was deregulated in a variety of human cancers. Recently, the company Epizyme published a study in Nature Chemical Biology[1] where the Ezh2 inhibitor EPZ005687 was revealed. Moreover, other studies have shown that this large family of proteins can serve as an excellent predictive biomarker and target for diagnostics products development.

Overall, the discovery of novel potent inhibitors for the histone methyltransferases family gives hope for many stagnated pharmaceutical R&D programs. The discovery of novel drug candidates for proteins, such as Ezh2, opens enormous possibilities not only in oncology research but in stem cell biology, neurodegeneration and other diseases.

In summary, this report will focus on recent developments in the assay and reagents sector for methyltransferase studies, diagnostics products based on histone methylation research and drug candidates targeting histone methyltransferase activity. It will describe in detail market participants in research and products development, and overall collaborations between different pharma/biotech companies during last two to three years. This report will evaluate the current situation and forecast possible outcomes of histone methyltransferases assay/reagents development, diagnostics and therapeutics field for the next five years.

SCOPE AND FORMAT

This report is essentially a business tool that can help market players properly evaluate new commercial opportunities in the epigenetic-related space of the histone methyltransferases segment in the context of research tools, diagnostics and therapeutics submarkets. The geographic scope of this study is global. This market is generally complex and consists of a number of different segments, each of which is affected differently by scientific and technological developments. This report identifies the main positive and negative factors affecting each segment, and forecasts market growth, future trends and product development in every major segment of this market.

ANALYST CREDENTIALS

Dr. Marianna Tcherpakov has more than eight years of experience as a bench scientist specializing in biochemistry, cell biology and industrial assay development. She has contributed to a number of scientific publications and holds several patents. She has expertise as an assay development scientist and is familiar with different research field trends and likely future developments.

Table of Contents

Histone Methyltransferases: Global Markets for Research Tools, Diagnostics and Drug Discovery

Chapter - 1: INTRODUCTION - Complimentary

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • SCOPE AND FORMAT
  • METHODOLOGY AND INFORMATION SOURCES
  • INTENDED AUDIENCE
  • ANALYST CREDENTIALS
  • RELATED BCC REPORTS
  • BCC ONLINE SERVICES
  • DISCLAIMER

Chapter - 2: SUMMARY

  • Table Summary: GLOBAL MARKET FOR HISTONE METHYLTRANSFERASES RESEARCH AND DEVELOPMENT, THROUGH 2018
  • Figure Summary: GLOBAL MARKET FOR HISTONE METHYLTRANSFERASES RESEARCH AND DEVELOPMENT, 2011-2018

Chapter - 3: INTRODUCTION TO HISTONE METHYLTRANSFERASES RESEARCH AND PRODUCT DEVELOPMENT

  • OVERVIEW
  • DNA METHYLATION
  • HISTONE MODIFICATIONS

Chapter - 4: DEVELOPMENT OF RESEARCH TOOLS AND REAGENTS FOR HISTONE METHYLTRANSFERASES STUDIES AND PRODUCT DEVELOPMENT

  • OVERVIEW
  • REAGENTS AND ASSAYS REQUIRED FOR HISTONE METHYLTRANSFERASES (HMT) STUDIES

Chapter - 5: HISTONE METHYLTRANSFERASES IN DRUG DISCOVERY AND THERAPEUTICS DEVELOPMENT

  • OVERVIEW
  • MARKET PARTICIPANTS IN THE HMT DRUG DISCOVERY SECTOR
  • CURRENT DRUG CANDIDATES AND HMT INHIBITORS IN DEVELOPMENT
  • DEALS IN THE EPIGENETICS SECTOR AS INDICATORS FOR MARKET DEVELOPMENT AND ACTIVITY
  • ADDITIONAL DRUG DISCOVERY TARGETS RELATED TO HMT RESEARCH

Chapter - 6: HISTONE METHYLTRANSFERASES IN DIAGNOSTICS AND BIOMARKER DEVELOPMENT

  • OVERVIEW
  • LUNG CANCER AND HISTONE MODIFICATIONS
  • PROSTATE CANCER AND HISTONE MODIFICATIONS
  • BREAST CANCER AND HISTONE MODIFICATIONS
  • LEUKEMIA AND HISTONE MODIFICATIONS
  • ESOPHAGEAL AND GASTRIC CANCERS AND HISTONE MODIFICATIONS
  • HISTONE MODIFICATIONS IN KIDNEY, LIVER AND PANCREATIC CANCERS
  • MARKET PARTICIPANTS IN EPIGENETIC DIAGNOSTICS SPACE

Chapter - 7: IMPORTANCE OF PATENTS IN HISTONE METHYLTRANSFERASE RESEARCH AND PRODUCT DEVELOPMENT

  • Table 56: WORLDWIDE PATENTS AND PATENT APPLICATION SEARCH IN HISTONE METHYLTRANSFERASE RESEARCH USING SPECIFIC KEYWORDS
  • Table 57: WORLDWIDE SEARCH FOR NUMBER OF PATENTS AND PATENT APPLICATIONS IN HISTONE METHYLTRANSFERASE RESEARCH ACCORDING TO ASSIGNEE

Chapter - 8: MARKET SUMMARY

  • Table 58: NUMBER OF PUBLICATIONS USING HISTONE METHYLTRANSFERASE AS SEARCH, 2000-2012
  • Figure 6: NUMBER OF PUBLICATIONS FROM 2000-2012 USING HISTONE METHYLTRANSFERASE AS SEARCH
  • Table 59: DISTRIBUTION OF DRUG DEVELOPMENT PROGRAMS IN EPIGENETIC SPACE
  • Table 60: GLOBAL MARKET FOR HISTONE METHYLTRANSFERASES RESEARCH AND DEVELOPMENT, THROUGH 2018
  • Figure 7: GLOBAL MARKET FOR HISTONE METHYLTRANSFERASES RESEARCH AND DEVELOPMENT, 2011-2018
  • Table 61: EXAMPLES OF MARKET PARTICIPANTS IN HISTONE METHYLTRANSFERASE SECTOR AND THEIR REPRESENTATIVE PRODUCTS

Chapter - 9: PROFILES OF SELECT COMPANIES

  • CELLCENTRIC LTD.
  • CONSTELLATION PHARMACEUTICALS
  • DOMAINEX
  • EPITHERAPEUTICS APS
  • EPIZYME, INC.
  • EISAI CO., LTD.
  • GLAXOSMITHKLINE (GSK)

Chapter - 10: LIST OF COMPANIES MENTIONED IN REPORT

  • ABCAM
  • ACTIVE MOTIF
  • ANASPEC
  • BELLBROOK LABS
  • BOEHRINGER INGELHEIM GMBH
  • CAYMAN CHEMICAL COMPANY
  • CELGENE CORPORATION
  • CELLCENTRIC LTD.
  • CELL SIGNALING TECHNOLOGY, INC.
  • CISBIO US
  • CONSTELLATION PHARMACEUTICALS
  • DIAGENODE INC. USA
  • DOMAINEX
  • EISAI CO., LTD.
  • EMD GROUP (EMD MILLIPORE)
  • ENZO LIFE SCIENCES, INC.
  • EPIGENOMICS AG
  • EPIGENTEK GROUP INC.
  • EPITHERAPEUTICS APS
  • EPIZYME, INC.
  • EXACT SCIENCES CORPORATION
  • G-BIOSCIENCES
  • GSK US
  • JOHNSON & JOHNSON
  • LIFE TECHNOLOGIES CORP.
  • MDXHEALTH, INC
  • MERCK CORPORATE HEADQUARTERS
  • METHYLGENE INC.
  • NEW ENGLAND BIOLABS
  • NOVARTIS INTERNATIONAL AG
  • ORION GENOMICS
  • PERKIN ELMER
  • PFIZER
  • PHARMACYCLICS, INC
  • PROGNOSDX HEALTH, INC.
  • RANA THERAPEUTICS INC.
  • REACTION BIOLOGY CORP.
  • RIBOMED BIOTECHNOLOGIES, INC.
  • SEQUENOM, INC.
  • SIGMA-ALDRICH
  • SIRTRIS
  • SYNDAX PHARMACEUTICALS, INC.
  • TAKEDA PHARMACEUTICALS U.S.A., INC.
  • THERMO FISHER SCIENTIFIC, INC.
  • VOLITIONRX
  • ZYMO RESEARCH CORPORATION

List of Tables

  • Summary Table: GLOBAL MARKET FOR HISTONE METHYLTRANSFERASES RESEARCH AND DEVELOPMENT, THROUGH 2018
    • Table 1: DIFFERENT CLASSES OF MODIFICATIONS IDENTIFIED ON HISTONES
    • Table 2: MAIN CATEGORIES IN HISTONE-MODIFICATION ENZYMES
    • Table 3: EXAMPLES OF HISTONE LYSINE METHYLATION AND ITS FUNCTIONAL OUTCOMES
    • Table 4: EXAMPLES OF HISTONE ARGININE METHYLATION AND ITS FUNCTIONAL OUTCOMES
    • Table 5: PRDM FAMILY MEMBERS, THEIR RELATED ENZYMATIC ACTIVITY AND BINDING PARTNERS
    • Table 6: EXAMPLES OF EPIGENETIC ALTERATIONS IN DIFFERENT PATHOLOGIES
    • Table 7: PERCENTAGE OF COMMERCIAL KITS GENERALLY PURCHASED FOR EPIGENETIC RESEARCH
    • Table 8: SELECT SUPPLIERS OF EPIGENETIC PRODUCTS
    • Table 9: PRODUCT CATEGORIES FOR HMT RESEARCH, COMPANIES MARKETING THE PRODUCTS AND AVERAGE PRICES
    • Table 10: GLOBAL MARKET FOR ANTIBODIES BY INDUSTRY SEGMENT, THROUGH 2016
    • Table 11: DISTRIBUTION OF VARIOUS APPLICATIONS FOR ANTIBODIES AS A RESEARCH TOOL
    • Table 12: MAIN MARKET PARTICIPANTS IN RESEARCH ANTIBODY SEGMENT AND THEIR RELATIVE MARKET SHARES
    • Table 13: SOURCES OF ANTIBODIES SUPPLY FOR RESEARCH AND THEIR PERCENTAGE ON THE MARKET
    • Table 14: PERCENTAGE USE OF SPECIFIC PROTEIN EXPRESSION TECHNIQUES
    • Table 15: GLOBAL MARKET FOR PROTEIN CHROMATOGRAPHY, THROUGH 2016
    • Table 16: AVERAGE SPENDING PER SCIENTIST ON PURIFICATION AND SEPARATION PRODUCTS
    • Table 17: GLOBAL MARKET SHARES OF RECOMBINANT ENZYME MARKET BY DIFFERENT TYPE OF ENZYME IN 2012
    • Table 18: GLOBAL RECOMBINANT ENZYME MARKET SHARES BY CUSTOMER
    • Table 19: LIST OF LYSINE HISTONE METHYLTRANSFERASES (KMT) AND THEIR SUBSTRATES
    • Table 20: LIST OF LYSINE HISTONE DEMETHYLASES (KDM) AND THEIR SUBSTRATES
    • Table 21: LIST OF ARGININE HISTONE METHYLTRANSFERASES AND THEIR SUBSTRATES
    • Table 22: LIST OF INHIBITORS USED IN HISTONE METHYLTRANSFERASE RESEARCH AND PRODUCT DEVELOPMENT
    • Table 23: SUBSTRATES FOR HMTS FOR IN VITRO STUDIES AND PERCENTAGE OF THEIR USE
    • Table 24: SELECT IN VITRO ASSAY AND COMMERCIAL KIT PROVIDERS
    • Table 25: LIST OF DIFFERENT ASSAY SET-UPS FOR HMT ACTIVITY MEASUREMENTS
    • Table 26: SURVEY OF SCIENTISTS' OPINIONS ABOUT EPIGENETICS SCREENING IN DRUG DISCOVERY
    • Table 27: STUDIES AND ASSAY DEVELOPMENT IN SPECIFIC DISEASE AREAS
    • Table 28: GLOBAL MARKET FOR RESEARCH TOOLS, REAGENTS AND ASSAYS FOR HISTONE METHYLTRANSFERASE STUDIES, THROUGH 2018
    • Table 29: ALTERED HISTONE MODIFICATIONS IN DIFFERENT PATHOLOGICAL CONDITIONS
    • Table 30: CURRENT APPROVED EPIGENETIC DRUGS ON THE MARKET
    • Table 31: SALES OF ZOLINZA, 2008-2010,
    • Table 32: SALES OF ISTODAX, 2011 AND 2012
    • Table 33: SALES OF VIDAZA, 2010-2012
    • Table 34: SALES OF DACOGEN, 2009-2011
    • Table 35: EXAMPLES OF EPIGENETIC DRUG DISCOVERY PROGRAMS
    • Table 36: COMPANIES DEVELOPING THERAPEUTICS WITH HISTONE METHYLTRANSFERASE AS A DRUG DISCOVERY TARGET
    • Table 37: RECENT DRUG DISCOVERY DEVELOPMENTS FOR HISTONE METHYLTRANSFERASE INHIBITORS
    • Table 38: POTENTIAL MARKETS FOR HMTS DRUG DISCOVERY
    • Table 39: DEALS IN EPIGENETICS MARKET IN THE LAST DECADE
    • Table 40: YEAR AND FUNDING AMOUNT FOR EPIGENETIC COMPANIES IN HMT DRUG DISCOVERY
    • Table 41: GLOBAL DRUG DISCOVERY MARKET VALUE FOR HISTONE METHYLTRANSFERASE RESEARCH, THROUGH 2018
    • Table 42: POTENTIAL EPIGENTICS TARGETS FOR DRUG DISCOVERY: EPIGENETIC ENZYMES CLASSES IMPORTANT IN COVALENT MODIFICATION OF DNA OR HISTONES
    • Table 43: RELATIONSHIP BETWEEN DEMETHYLASES, METHYLTRASNFERASES AND THEIR RESPECTIVE HISTONE METHYLATION SITES
    • Table 44: RELATIONSHIP BETWEEN HISTONE METHYLATION, METHYL READERS AND THEIR FUNCTIONS
    • Table 45: NUMBER OF PUBMED PUBLICATIONS ON BIOMARKERS USING DIFFERENT EPIGENETIC MECHANISMS, 2012
    • Table 46: DNA METHYLATION EVENTS AND THEIR RELATION TO DIFFERENT PATHOLOGIES
    • Table 47: NUMBER OF PUBLICATIONS IN HISTONE METHYLATION AREA BASED ON DIFFERENT SEARCH CRITERIA
    • Table 48: RELATIONSHIP BETWEEN HISTONE METHYLATION AND CANCER PROGNOSIS
    • Table 49: DIFFERENT HISTONE METHYLTRANSFERASES AND THEIR ASSOCIATION TO CANCER DEVELOPMENT
    • Table 50: DEMETHYLASES AND THEIR ASSOCIATIONS WITH CANCER DEVELOPMENT
    • Table 51: GLOBAL BIOMARKERS MARKET, THROUGH 2015
    • Table 52: SELECT EPIGENTICS DIANGOSTICS COMPANIES
    • Table 53: EXAMPLES OF AVERAGE REVENUES IN EPIGENETIC DIAGNOSTICS COMPANIES
    • Table 54: GLOBAL MARKET FOR HISTONE METHYLATION IN BIOMARKERS AND DIAGNOSTICS PRODUCT DEVELOPMENT, THROUGH 2018
    • Table 55: DIAGNOSTICS MARKET VALUES IN ONCOLOGY SECTOR, 2013
    • Table 56: WORLDWIDE PATENTS AND PATENT APPLICATION SEARCH IN HISTONE METHYLTRANSFERASE RESEARCH USING SPECIFIC KEYWORDS
    • Table 57: WORLDWIDE SEARCH FOR NUMBER OF PATENTS AND PATENT APPLICATIONS IN HISTONE METHYLTRANSFERASE RESEARCH ACCORDING TO ASSIGNEE
    • Table 58: NUMBER OF PUBLICATIONS USING HISTONE METHYLTRANSFERASE AS SEARCH, 2000-2012
    • Table 59: DISTRIBUTION OF DRUG DEVELOPMENT PROGRAMS IN EPIGENETIC SPACE
    • Table 60: GLOBAL MARKET FOR HISTONE METHYLTRANSFERASES RESEARCH AND DEVELOPMENT, THROUGH 2018
    • Table 61: EXAMPLES OF MARKET PARTICIPANTS IN HISTONE METHYLTRANSFERASE SECTOR AND THEIR REPRESENTATIVE PRODUCTS

List of Figures

  • Summary Figure: GLOBAL MARKET FOR HISTONE METHYLTRANSFERASES RESEARCH AND DEVELOPMENT, 2011-2018
    • Figure 1: SCHEMATIC PRESENTATION OF METHYLATION REACTION
    • Figure 2: SCHEMATIC REPRESENTATION OF HMTS ASSAY DEVELOPMENT
    • Figure 3: GLOBAL MARKET FOR RESEARCH TOOLS, REAGENTS AND ASSAYS FOR HISTONE METHYLTRANSFERASE STUDIES, 2011-2018
    • Figure 4: GLOBAL DRUG DISCOVERY MARKET VALUE FOR HISTONE METHYLTRANSFERASE RESEARCH, 2011-2018
    • Figure 5: GLOBAL MARKET FOR HISTONE METHYLATION IN BIOMARKERS AND DIAGNOSTICS PRODUCT DEVELOPMENT, 2011-2018
    • Figure 6: NUMBER OF PUBLICATIONS FROM 2000-2012 USING HISTONE METHYLTRANSFERASE AS SEARCH
    • Figure 7: GLOBAL MARKET FOR HISTONE METHYLTRANSFERASES RESEARCH AND DEVELOPMENT, 2011-2018
Back to Top